Leadership

Antoine J. Yver

Independent Chair

Dr. Antoine J. Yver is an accomplished oncology leader and physician–scientist with more than three decades of experience shaping global cancer drug development. Over his career, he has led or contributed to the approval of multiple transformative therapies, including osimertinib and trastuzumab deruxtecan (ENHERTU®), and has been instrumental in building some of the most successful oncology portfolios in the industry. Formerly Head of Global Oncology R&D at Daiichi Sankyo and senior executive at AstraZeneca, Dr. Yver has a track record of driving innovation, forging landmark ADC partnerships, and delivering life-changing treatments to patients. Today, he serves on several boards and scientific committees, including Sanofi, Duality Biologics, D3 Bio, and ONA Therapeutics, where he continues to mentor and guide the next generation of biotech innovators. Trained as a pediatric oncologist and immunologist in Paris, he combines deep medical expertise with strategic vision and an unwavering commitment to improving patient outcomes.